Genetic Technologies Limited operates as a biotechnology company. BREVAGen The company focuses on expanding its genetic testing business in the Asia-Pacific region and, with the addition of the BREVAGen breast cancer risk assessment test, in the U.S.A. and Europe. In 2012, the company had received European CE Mark approval for BREVAGen, which would allow BREVAGen to be sold in the EU and other countries that recognise the CE Mark. Other Areas The company pursues commercial opportunities in other areas of activity: out-licensing non-coding patents worldwide; and supporting a late-stage research and development project. Genetic Testing Business The company provides paternity and related testing services in Australia. Its service testing laboratory in Fitzroy (an inner suburb of Melbourne, Victoria) is a non-Government genetic testing service provider in Australia. The company provides DNA-based individuality testing for the resolution of disputed paternity and the determination of familial relationships for immigration purposes. Other types of tests that the company could offer include Y chromosome testing, Mitochondrial DNA testing, Sibship testing, Maternity testing, DNA typing, Grandparent analysis, and Antenatal DNA testing. The company issues reports for the Family Court in Australia and provides similar services internationally for the Department of Immigration and Citizenship (DIAC). The RareCellect solution The company has developed a proprietary sampling device using materials and design features which would ensure safe, non-traumatic sampling of the optimal region of the cervix to yield fetal genetic material. Prototypes of the device have been manufactured and tested on approximately 250 women to sample fetal material during early stages of pregnancy (6 to 12 weeks). The device is protected by the U.S. provisional patent. The company has also developed processing methods that could deliver fetal cells or DNA in a form that is suitable for testing using any of the approved diagnostic methodologies. These processing methods are also covered by provisional patents. Patent Portfolio The company has 18 issued patents and 12 patent applications in the United States. The major families of patents in the portfolio include Intron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGen; Laboratory Techniques; Ancestral Haplotypes; Athletic Performance; and RareCellect Project. Licenses and Commercial Collaborations The company has granted commercial licenses to a total of 72 licensees and 6 research licenses. Environmental Regulations The company’s operations are subject to environmental regulations under Australian State legislation. In particular, the company is subject to the requirements of the Environment Protection Act 1993. Significant Events Sale of heritage Australian Genetics business: In September 2014, the had signed a binding contract of sale for its heritage Australian Genetics business to Specialist Diagnostics Services Ltd, the wholly owned pathology subsidiary of Primary Health Care Ltd. The Australian Genetics business provides diagnostic and sequencing services encompassing Australia-only medical, forensic, paternity and animal genomic testing.
genetic tech ltd-sp adr (GENE:NASDAQ CM)
60-66 Hanover Street
Fitzroy, VIC 3065
Phone: 61 3 8412 7000
Fax: 61 3 8412 7040www.gtglabs.com
|Agilent Technologies Inc||$40.70 USD||-0.11|
|Sonic Healthcare Ltd||A$20.47 AUD||0.00|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact GENETIC TECH LTD-SP ADR, please visit www.gtglabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.